Advances in the molecular diagnosis of hepatitis C and their clinical implications

Mayo Clinic Proceedings

Volumn 76, Issue 9, 2001, Pages 911-920

  Germer, Jeffrey J ^a   Zein, Nizar N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIBODY RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; QUALITATIVE DIAGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SEROLOGY; TREATMENT PLANNING;

EID: 0034851154     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.9.911     Document Type: Review

References (87)

1. EASL international consensus conference on hepatitis C, Paris, 26-28 February 1999: Consensus statement
2. Statement: Management of hepatitis C
3. Liver transplantation for chronic viral hepatitis
4. Recurrent and new hepatitis C virus infection after liver transplantation
5. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
6. Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease
7. The Taiwanese hepatitis C virus genome: Sequence determination and mapping the 5′ termini of viral genomic and antigenomic RNA
8. Sequence analysis of the putative structural genes of hepatitis C virus from Japanese and European origin
9. There are two major types of hepatitis C virus in Japan
10. Distribution of plural HCV types in Japan
11. Evidence of two major genotypes of hepatitis C virus in France and close relatedness of the predominant one with the prototype virus
12. Two French genotypes of hepatitis C virus: Homology of the predominant genotype with the prototype American strain
13. Hypervariable regions in the putative glycoprotein of hepatitis C virus
14. Characterization of the terminal regions of hepatitis C viral RNA: Identification of conserved sequences in the 5′ untranslated region and poly(a) tails at the 3′ end
15. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: Comparative study of four distinct genotypes
16. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
17. At least five related, but distinct, hepatitis C viral genotypes exist
18. A proposed system for the nomenclature of hepatitis C viral genotypes
19. Hepatitis C genotypes: Current trends and future implications
20. Hepatitis C virus type 1b (II) infection in France and Italy
21. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy
22. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
23. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
24. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
25. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis
26. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive results?
27. Hepatitis C: Diagnostic assays
28. Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction
29. HCV confirmatory testing of blood donors
30. Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory
31. Indeterminate second-generation hepatitis C recombinant immunoblot test: Detection of hepatitis C virus infection by polymerase chain reaction
32. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay
33. Indeterminate results of the second-generation hepatitis C virus (HCV) recombinant immunoblot assay: Significance of high-level c22-3 reactivity and influence of HCV genotypes
34. Genotype-dependent serologic reactivities in patients infected with hepatitis C virus in the United States
35. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay: A clinico-pathologic study and demonstration of the usefulness of a third-generation assay
36. Frequency and characteristics of post-transfusion hepatitis in Greece with emphasis on hepatitis C: Comparing second- and third-generation assays
37. Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays
38. Influence of hepatitis C virus (HCV) genotypes on HCV recombinant immunoblot assay patterns
39. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay
40. Use of conserved sequences from hepatitis C virus for the detection of viral RNA in infected sera by polymerase chain reaction
41. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay
42. Impact of specimen handling and storage on detection of hepatitis C virus RNA
43. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA
44. Diagnostic molecular microbiology: Current challenges and future directions
45. Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA
46. Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: Comparison with nested amplification and antibody testing
47. Evaluation of the automated COBAS AMPLICOR hepatitis C virus PCR system
48. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory
49. COBAS AMPLICOR: Fully automated RNA and DNA amplification and detection system for routine diagnostic PCR
50. Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management
51. Second generation of the automated COBAS AMPLICOR HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant
52. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics
53. Clinical laboratory evaluation of a new sensitive and specific assay for qualitative detection of hepatitis C virus RNA in clinical specimens
54. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays
55. Quantitation of HCV-replication using one-step competitive reverse transcription-polymerase chain reaction and a solid phase, colorimetric detection method
56. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: High-titer viremia correlates with advanced stage of disease
57. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease
58. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
59. Standardization of hepatitis C virus RNA quantification
60. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
61. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method
62. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays
63. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays
64. Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test
65. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology
66. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA
67. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C
68. Quantification of serum hepatitis C virus RNA
69. Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection
70. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States
71. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
72. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: Epidemiological applications
73. Identification of the third major genotype of hepatitis C virus in France
74. Hepatitis C virus genotypes in France: Comparison of clinical features of patients infected with HCV type I and type II
75. Detection of three types of hepatitis C virus in blood donors: Investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities
76. Use of the 5′ noncoding region for genotyping hepatitis C virus
77. Second-generation line probe assay for hepatitis C virus genotyping
78. Variability of hepatitis C virus
79. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
80. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test
81. Two distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core protein
82. Hepatitis C virus (HCV) core serotypes in chronic HCV infection
83. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3
84. Antigenicities of Group I and II hepatitis C virus polypeptides - Molecular basis of diagnosis
85. Serological determination of hepatitis C virus subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a recombinant immunoblot assay
86. Serological determination of hepatitis C virus genotype: Comparison with a standardized genotyping assay
87. Evaluation of a novel serotyping system for hepatitis C virus: Strong correlation with standard genotyping methodologies